Clinical Trial Results:
Estudio de 12 semanas de duración para evaluar la función pulmonar durante 24 horas de Furoato de Fluticasona (FF)/Vilanterol (VI) en polvo para inhalación (FF/VI en polvo para inhalación) una vez al día en comparación con Salmeterol/Propionato deFluticasona (PF) en polvo para inhalación dos veces al día en sujetos con enfermedad pulmonar obstructiva crónica (EPOC). "A 12-Week Study to Evaluate the 24 Hour Pulmonary Function of Fluticasone Furoate (FF)/Vilanterol (VI) Inhalation Powder (FF/VI Inhalation Powder) Once Daily Compared with Salmeterol/Fluticasone Propionate (FP) Inhalation Powder Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)".
Summary
|
|
EudraCT number |
2010-021059-25 |
Trial protocol |
ES DE BE IT |
Global completion date |
19 Oct 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Mar 2016
|
First version publication date |
06 Mar 2016
|
Other versions |
|
Summary report(s) |
113107-FDAAA-Result-Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.